Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Seyed Moein Seyhoun"'
Autor:
Faezeh Hosseinzadeh, Iman Seyhoun, Jafar Ai, Benyamin Parseh, Zeinab Ghazvinian, Javad Verdi, Shahrokh Abdolahi, Milad Mirmoghtadaei, Mahdi Shadnoush, Seyed Moein Seyhoun, Saieh Hajighasemlou
Publikováno v:
Asian Pacific Journal of Cancer Prevention : APJCP
Objective: Hepatocellular carcinoma (HCC) is the most common liver malignancy. Sorafenib is the first-line systemic treatment for advanced HCCs. However, due to safety concerns, researchers are now looking for ways to boost the efficacy of the medica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::845320b8fe07d81b930de687182f86af
https://doi.org/10.31557/apjcp.2019.20.1.263
https://doi.org/10.31557/apjcp.2019.20.1.263
Autor:
Milad Mirmoghtadaei, Faezeh Hosseinzadeh, Jafar Ai, Saieh Hajighasemlou, Ali Akbar Alizadeh, Iman Seyhoun, Mohsen Nikbakht, Javad Verdi, Seyed Moein Seyhoun, Samad Muhammadnejad
Publikováno v:
Journal of Cellular Physiology. 234:9495-9503
Aim Hepatocellular carcinoma (HCC) is the most common liver malignancy and the second leading cause of cancer-related deaths in the world. Sorafenib is the first-line treatment of HCC. Although sorafenib has positive effects on the survival of patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::addb1cdc24cb991b7489649ca91c563f
https://doi.org/10.1002/jcp.27637
https://doi.org/10.1002/jcp.27637